Streamlining GLP-1 Prior Auth in Texas

The Challenge of GLP-1 Prior Authorization in Texas

Healthcare organizations in Texas face substantial operational burdens managing GLP-1 prior authorizations. Distinguishing between Type 2 Diabetes (T2D) and obesity indications, navigating frequent step-therapy requirements, and addressing varying obesity-coverage policies among payers contribute to high denial rates and administrative overhead. Without automation, the volume of these PAs significantly impacts prescriber and prior authorization coordinator workflows.

Key Operational Considerations for GLP-1 PA in Texas

• **Diverse Payer Landscape:** Managing unique PA criteria across Texas's commercial health plans and state-specific Medicaid managed care organizations.
• **Indication-Specific Criteria:** Accurately routing PAs based on T2D versus obesity indications, as coverage varies widely.
• **Step Therapy Compliance:** Documenting prior medication trials (e.g., metformin) as required by payer policies and ADA Standards of Care.
• **Documentation Requirements:** Ensuring all necessary clinical data, such as BMI and A1C levels, is accurately pulled from the EMR.
• **High Volume Management:** Handling the significant increase in PA requests for drugs like Ozempic, Wegovy, Mounjaro, Zepbound, and Saxenda efficiently.

Klivira's Automated Approach to GLP-1 PA Workflows

Klivira's platform automates the intricate steps involved in GLP-1 prior authorizations, reducing manual effort and improving approval rates. Our solution is designed to handle the specific challenges presented by this high-volume drug category, from initial indication classification to specialty pharmacy fulfillment, ensuring a streamlined process for providers in Texas.

Core Automation Capabilities for GLP-1 Prior Authorizations

• **Indication-Aware Routing:** Automatically classifying T2D versus obesity indications from EMR data to apply correct payer criteria.
• **Per-Payer Obesity-Coverage Logic:** Dynamically routing based on each payer's specific obesity benefit status (covered, restricted, not-covered), as tracked by Klivira's policy engine.
• **Automated Step Therapy Documentation:** Extracting and submitting required clinical history, such as metformin trial details and comorbidity status, via FHIR-enabled integrations.
• **Brand-Specific PA Criteria:** Applying unique authorization logic for drugs like Ozempic, Wegovy, Mounjaro, Zepbound, and Saxenda based on specific product guidelines.
• **Integrated Specialty Pharmacy Fulfillment:** Facilitating post-approval routing to specialty pharmacies for seamless medication delivery.
• **Patient Financial Counseling Integration:** Surfacing manufacturer copay programs and alternative coverage paths when an obesity indication is denied by the payer.

Integrating with Texas Healthcare Systems for Seamless PA

Klivira integrates directly with major EMR systems commonly used across Texas health systems and clinics, leveraging SMART on FHIR for secure data exchange. This enables automated extraction of clinical documentation required for GLP-1 PAs, reducing manual chart review. Our platform supports both traditional X12 278 transactions and emerging ePA standards like Da Vinci PAS, ensuring broad connectivity with payer portals and pharmacy benefit managers (PBMs) relevant to the Texas market.